"Powering the Future with Foresight: Roche Oncology Forum on Personalized Medicine Concludes Successfully"

On July 9, 2022, hosted by Roche Pharmaceuticals“Visionary • Action”Roche Oncology Summit: Personalized Medicine SessionThe cloud-based live stream has concluded successfully. As a professional academic conference in the field of oncology, this event brought together numerous distinguished experts from clinical practice, investment, academia, and industry. It gathered cutting-edge innovative research and insights, offering new perspectives and directions for the development of personalized medicine in the oncology sector.

This event primarily focuses onPersonalized Health Upgrades, Innovation Ecosystem Empowerment, and Building an Innovative Oncology Service SystemDiscussions were conducted across three key areas, with six distinguished guests specially invited to serve as moderators for the forum and roundtable sessions: Professor Zeng Musheng, Deputy Director of Sun Yat-sen University Cancer Center; Professor Shen Baiyong, Deputy Director of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Professor Chen Lei, Deputy Director of West China Hospital, Sichuan University; Professor Zhou Jian, Deputy Director of Zhongshan Hospital, Fudan University; Professor Chen Kexin, Deputy Director of Tianjin Medical University Cancer Institute and Hospital; and Mr. Liang Zhanchao, Partner at Mifang Health Fund.

At the outset of the event, a conference guest delivered the opening remarks, stating: “Today, technological innovation is advancing at an unprecedented pace, and our evidence-based approach to disease and health is becoming increasingly scientific, precise, and digital.”We will continuously build and summarize, leveraging the latest cutting-edge technologies,Improve treatment efficiency and promote the widespread adoption of personalized medicine and precision medicine.

FromVice President, Medical and Personalized Healthcare Department, Roche Pharmaceuticals ChinaMr. Li Bin also elaborated on Roche’sVision: Hope to realize“Deliver three to five times the patient benefit and value at half the social cost”, to build an open, collaborative, and innovative domestic healthcare ecosystem in China, thereby supporting the grand blueprint of Healthy China 2030.

It is understood that personalized medicine is a core strategic priority for Roche globally. Having cultivated this field for many years and leveraging its extensive experience in both pharmaceuticals and diagnostics, Roche has firmly established itself as a global leader in oncology and a pioneer in personalized medicine.

To promote the development of the healthcare sector and industry, and to strengthen medical innovation and the translation of research achievements into practical applications, this event is co-hosted by the Shanghai Medical Innovation and Development Foundation and Roche Pharmaceuticals.““Precision Medicine Research and Industrial Innovation Development Fund — Personalized Medicine Incubation Project”Officially launched, jointly wishing for a “Healthy China 2030” a bright future.Participating guests includeProfessor Zhang Zongjiu, Executive Vice Dean of the School of Hospital Management, Tsinghua UniversityProfessor Rao Keqin, President of the Chinese Society of Health Economics,Chinese Academy of SciencesAcademicianFan JiaAcademician,Chinese Academy of SciencesAcademicianSong ErweiAcademician,The Royal Academy of EngineeringAcademicianAcademician Yang Guangzhong、Professor Wang Bo, Secretary-General of the Shanghai Medical Innovation and Development Foundation、Bian Xin, President of Roche Pharmaceuticals ChinaMs. and Mr. Li Bin, Vice President of the Medical and Personalized Healthcare Department of Roche Pharmaceuticals China。“Precision Medicine Research and Industrial Innovation Development Fund—Personalized Medicine Incubation Project” focuses primarily on oncology, while also covering neurology and ophthalmology, with plans to fundTen guided projects in technology, R&D, and innovation provide a capacity-building and business skills development system aligned with the project stages of clinical teams, to enrich the development of digital products in the healthcare sector, drive improvements in medical efficiency, and enhance patient treatment outcomes.

In terms of content sharing, this event has specially invited Professor Tian Xu, Chair Professor of Genetics and Vice President of Westlake University, as well asProfessor Amye Tevaarwerk, Chief of Medical Oncology at Mayo Clinic and Vice Chair of the National Comprehensive Cancer Network (NCCN) EHR Oncology Group, delivered an in-depth presentation.

Professor Tian Xu, Chair Professor of Genetics and Vice President of Westlake University, provided an in-depth analysis through three case studies, focusing on: how to precisely match a drug with a specific type of tumor; how to identify novel, precise drug targets and therapies for a particular tumor; and how to develop drugs tailored to individual-specific tumor gene mutations and changes in gene expression. He proposed that predicting drug responses and activating immune-based therapies based on each patient’s unique profile of gene expression, gene mutations, and tumor characteristics will be a key direction for future development and is expected to yield highly effective therapeutic outcomes.

Professor Amye Tevaarwerk, Chief of the Division of Medical Oncology at Mayo Clinic and Vice Chair of the National Comprehensive Cancer Network (NCCN) Electronic Health Records (EHR) Oncology Group, drew upon her work at Mayo Clinic and personal research to provide an in-depth analysis of how novel information technologies can enhance the patient experience for cancer care. She examined this topic from multiple dimensions, including website utilization, hospital systems, patient communication, out-of-hospital management, and remote monitoring. Professor Tevaarwerk emphasized that effective disease course management and patient education during treatment can significantly improve therapeutic outcomes.

In addition, Ms. Shen Xiafang, Director of the Medical and Personalized Healthcare Department at Roche Pharmaceuticals China,3 positionsForeign Guest from Roche’s Global HeadquartersKelly Haenlein、Ryan Copping, Shemra Rizzo, Professor Zhang Sheng, President of Huazhou People's Hospital, and Mr. Jiang Tianjiao, Dean of VCBeat Eggshell Research Institute,andProfessor Dai Min, Director of the Laboratory for Disease Prevention and Early Intervention, Peking Union Medical College HospitalOn Roche’s Development Strategy for Personalized Medicine, and RochePersonalized Medicine Empowers R&D, in-depth sharing was conducted on topics such as community-based liver cancer screening under medical consortia, technological innovation and value creation, and population cohort studies within the framework of precision medicine.

At the conclusion of the event, guided by the two moderators—Professor Chen Kexin, Vice President of Tianjin Medical University Cancer Institute and Hospital, and Mr. Liang Zhanchao, Partner at Mifang Health Fund—the following distinguished guests participated: Professor Zhang Xinxin, Director of the Clinical Research Center at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Professor Shi Lei, Director of the Department of Radiation Oncology at the Cancer Hospital of the University of Chinese Academy of Sciences; Ms. Wang Jingjing, Executive Director of the Global Health Industry Innovation Center; Ms. Lei Juan, Director of the West China Metastasis Center at West China Hospital, Sichuan University; Professor Liang Shaolin, Deputy Director of the Innovation Engineering Office at the Sixth Industry Research Institute of Fudan University; Professor Zhao Gansen, Deputy Director of the Guangdong Data Science Engineering Center; and Ms. Shen Xiafang, Director of the Medical and Personalized Healthcare Department at Roche Pharmaceuticals China.Seven panelists engaged in vigorous discussion and knowledge sharing on the topic of “Building an Oncology Innovation System and a Closed-Loop Service Model.” Drawing from perspectives spanning clinical practice, technology, capital, hospital/university technology transfer, and industry, they addressed pain points in scientific translation, shared translational experiences, and explored ecosystem development. Their insights offered new thinking and strategic directions for Roche’s incubation platform and ecosystem building.

This year marks the global founding of Roche.Marking its 126th anniversary, this year also represents Roche’s 28th year of establishing a strong presence in China. After more than two decades of dedicated cultivation and operation, the Roche Oncology Summit has become one of the most important annual academic conferences for oncology professionals in China. This platform serves not only as a premier event for learning and exchange among experts across the industry chain but also as a vital window and channel for introducing Roche’s global headquarters’ expertise and innovative digital tools to China, thereby empowering Chinese patients. We believe that with the advancement and deepening of precision medicine and personalized healthcare, supported by continuously evolving digital technologies and driven by innovation and collaboration among diverse experts within the ecosystem, every patient will receive optimal treatment methods and precise medical services in the future. We look forward to the early arrival of this day.